Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. Other stock markets 03:08:30 2023-11-22 am EST			5-day change	1st Jan Change
5.62 ^HKD	-0.71%		-.--%	-.--%

Apr. 01	Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%	MT
Mar. 28	Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Venus MedTech Inc. acquired InterValve Inc.

June 13, 2017

Venus MedTech (HangZhou) Inc. acquired InterValve Inc. on June 13, 2017. Starting from June 2017, Venus Medtech will be responsible for the global production and sales of V8 and TAV8. Venus MedTech (HangZhou) Inc. completed the acquisition of InterValve Inc. on June 13, 2017.

Latest news about Venus Medtech (Hangzhou) Inc.

Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%	Mar. 31	MT
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Venus Medtech Inc.(SEHK:2500) dropped from S&P Global BMI Index	Mar. 17	CI
Venus Medtech Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away	Feb. 07	CI
Venus Medtech Names Former 3SBio Finance Chief as CFO	Jan. 04	MT
Venus Medtech Inc. Appoints Fei Wang as the Chief Financial Officer	Jan. 04	CI
Venus Medtech Gets Trading Resumption Guidance	Dec. 27	MT
Venus Medtech Inc. Approves Mr. Liqiao Ma as an Executive Director	Dec. 15	CI
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action	Nov. 28	MT
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China	Nov. 22	MT
Venus Medtech Inc. Announces Executive Changes	Nov. 20	CI
Venus Medtech Names Joint CEO	23-09-24	MT
Venus Medtech Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023	23-09-22	CI
Venus Medtech's H1 Attributable Loss Widens	23-08-31	MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
US FDA Grants Clinical Trial Approval to Venus Medtech's Pulmonary Valve Replacement	23-08-06	MT
Venus Medtech Inc. Announces it's Self-Developed Transcatheter Pulmonary Valve Replacement System VenusP-Valve Received the Approval of IDE (Investigational Device Exemption) Application from the US Food and Drug Administration	23-08-06	CI
Venus Medtech’s General Manager Boosts Shareholding to 12%	23-06-13	MT
Venus Medtech Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary	23-06-02	CI
Venus Medtech Inc. Announces Resignation of Haiyue Ma as CFO	23-06-02	CI
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Venus Medtech Completes Patient Enrollment for Confirmatory Trial of Liwen RF Ablation System	23-03-03	MT
Venus Medtech Inc. Announces Completion of Full Patient Enrollment for Confirmatory Clinical Trial of Liwen RF in China	23-03-03	CI
Venus Medtech Inc. Announces Board Changes	23-01-30	CI
Venus Medtech Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman	22-12-13	CI

Chart Venus Medtech (Hangzhou) Inc.

Duration

Period

More charts

Company Profile

Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Venus Medtech (Hangzhou) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.157 CNY

Average target price

7.414 CNY

Spread / Average Target

+43.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
VENUS MEDTECH (HANGZHOU) INC.	-.--%	314M
STRYKER CORPORATION	+11.84%	127B
SMITH & NEPHEW PLC	-8.39%	10.68B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.71%	8.59B
INSPIRE MEDICAL SYSTEMS, INC.	+14.99%	7.09B
GLAUKOS CORPORATION	+27.16%	5.07B
AXONICS, INC.	+6.81%	3.39B
ENOVIS CORPORATION	-0.98%	3.04B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-13.77%	2.02B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-9.83%	2B

Medical Devices & Implants